June 26, 2025 • 3 mins
In a significant breakthrough in the fight against malaria, several recent developments have marked a new era in the global effort to combat this debilitating disease.
Over the past two days, a major announcement has been made regarding the pricing of the world's first malaria vaccine, RTS,S. The vaccine, developed by GSK, the nonprofit organization PATH, and other partners, is set to see its price slashed by more than half. According to a commitment by drugmakers Bharat Biotech and GSK, the cost per dose will drop to less than $5 in endemic countries by 2028. This reduction is made possible through process improvements, expanded production capacity, and cost-effective manufacturing, along with minimal profit margins. The technology transfer of production from GSK to Bharat Biotech, which began in 2021, will be fully realized by 2028, facilitating this price cut[3].
This price reduction is particularly significant given the historical challenges in developing and distributing malaria vaccines. Malaria vaccines have been in development since the 1960s, with substantial progress made in the last decade. The World Health Organization (WHO) recommended the widespread use of the RTS,S/AS01 malaria vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission in October 2021. More recently, the WHO approved a second malaria vaccine, R21/Matrix-M, for use in malaria-endemic countries[5].
In addition to the pricing news, there has been an innovative advancement in vaccine delivery technology. Researchers from Oxford have developed programmable microcapsules that can deliver vaccines in stages, potentially eliminating the need for booster shots. This 'single shot' malaria vaccine delivery system could transform global immunization efforts by simplifying the vaccination process and improving compliance, especially in regions where access to healthcare is limited[1].
These developments come as countries are ramping up their malaria vaccination programs. For instance, Uganda recently launched the largest malaria vaccine introduction to date, targeting 1.1 million children under two years with the R21/Matrix-M vaccine. This vaccine is administered in four doses at 6, 7, 8, and 18 months[4].
The ongoing efforts to enhance malaria vaccination highlight the complex challenges associated with developing vaccines against this parasite. Malaria parasites have a complex life cycle and produce thousands of potential antigens, making it difficult to achieve lifelong protection through vaccination. However, current malaria vaccines, such as RTS,S and R21/Matrix-M, have shown promising results, reducing uncomplicated malaria by around 40%, severe malaria by about 30%, and all-cause mortality by 13%[5].
As these advancements continue to shape the landscape of malaria prevention, they underscore the commitment of global health organizations, researchers, and pharmaceutical companies to combating this persistent and deadly disease.
This content was created in partnership and with the help of Artificial Intelligence AI
Over the past two days, a major announcement has been made regarding the pricing of the world's first malaria vaccine, RTS,S. The vaccine, developed by GSK, the nonprofit organization PATH, and other partners, is set to see its price slashed by more than half. According to a commitment by drugmakers Bharat Biotech and GSK, the cost per dose will drop to less than $5 in endemic countries by 2028. This reduction is made possible through process improvements, expanded production capacity, and cost-effective manufacturing, along with minimal profit margins. The technology transfer of production from GSK to Bharat Biotech, which began in 2021, will be fully realized by 2028, facilitating this price cut[3].
This price reduction is particularly significant given the historical challenges in developing and distributing malaria vaccines. Malaria vaccines have been in development since the 1960s, with substantial progress made in the last decade. The World Health Organization (WHO) recommended the widespread use of the RTS,S/AS01 malaria vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission in October 2021. More recently, the WHO approved a second malaria vaccine, R21/Matrix-M, for use in malaria-endemic countries[5].
In addition to the pricing news, there has been an innovative advancement in vaccine delivery technology. Researchers from Oxford have developed programmable microcapsules that can deliver vaccines in stages, potentially eliminating the need for booster shots. This 'single shot' malaria vaccine delivery system could transform global immunization efforts by simplifying the vaccination process and improving compliance, especially in regions where access to healthcare is limited[1].
These developments come as countries are ramping up their malaria vaccination programs. For instance, Uganda recently launched the largest malaria vaccine introduction to date, targeting 1.1 million children under two years with the R21/Matrix-M vaccine. This vaccine is administered in four doses at 6, 7, 8, and 18 months[4].
The ongoing efforts to enhance malaria vaccination highlight the complex challenges associated with developing vaccines against this parasite. Malaria parasites have a complex life cycle and produce thousands of potential antigens, making it difficult to achieve lifelong protection through vaccination. However, current malaria vaccines, such as RTS,S and R21/Matrix-M, have shown promising results, reducing uncomplicated malaria by around 40%, severe malaria by about 30%, and all-cause mortality by 13%[5].
As these advancements continue to shape the landscape of malaria prevention, they underscore the commitment of global health organizations, researchers, and pharmaceutical companies to combating this persistent and deadly disease.
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
In a significant breakthrough in the fight against malaria. Several
recent developments have marked a new era in the global
effort to combat this debilitating disease. Over the past two days,
a major announcement has been made regarding the pricing of
the world's first malaria vaccine RTSs. The vaccine developed by GSK,
(00:20):
the nonprofit organization PATH and other partners, is set to
see its price slashed by more than half. According to
a commitment by drug makers Barrot Biotech and GSK, the
cost per dose will drop to less than five dollars
in endemic countries by twenty twenty eight. This reduction is
made possible through process improvements, expanded production capacity, and cost
(00:42):
effective manufacturing, along with minimal profit margins. The technology transfer
of production from GSK to Barrot Biotech, which began in
twenty twenty one, will be fully realized by twenty twenty eight,
facilitating this price cut. This price reduction is particularly significant
given the historical challenges in developing and distributing malaria vaccines.
(01:05):
Malaria vaccines have been in development since the nineteen sixties,
with substantial progress made in the last decade. The World
Health Organization WHO recommended the widespread use of the rts
SA zero one malaria vaccine among children in Sub Saharan
Africa and other regions with moderate to high malaria transmission
in October twenty twenty one. More recently, the WHO approved
(01:29):
a second malaria vaccine, R twenty one Matrix M for
use in malaria endemic countries. In addition to the pricing news,
there has been an innovative advancement in vaccine delivery technology.
Researchers from Oxford have developed programmable microcapsules that can deliver
vaccines in stages, potentially eliminating the need for booster shots.
(01:51):
This single shot malaria vaccine delivery system could transform global
immunization efforts by simplifying the vaccination process and improving compliance,
especially in regions where access to healthcare is limited. These
developments come as countries are ramping up their malaria vaccination programs.
For instance, Uganda recently launched the largest malaria vaccine introduction
(02:15):
to date, targeting one point one million children under two
years with the R twenty one Matrix M vaccine. This
vaccine is administered in four doses at six, seven, eight,
and eighteen months. The ongoing efforts to enhance malaria vaccination
highlight the complex challenges associated with developing vaccines against this parasite.
(02:36):
Malaria parasites have a complex life cycle and produce thousands
of potential antigens, making it difficult to achieve lifelong protection
through vaccination. However, current malaria vaccines such as rts S
and R twenty one matrix M have shown promising results,
reducing uncomplicated malaria by around forty percent, severe malaria by
(02:56):
about thirty percent, and all cause mortality by thirty ten.
As these advancements continue to shape the landscape of malaria prevention,
they underscore the commitment of global health organizations, researchers, and
pharmaceutical companies to combating this persistent and deadly disease.
In a significant breakthrough in the fight against malaria. Several
recent developments have marked a new era in the global
effort to combat this debilitating disease. Over the past two days,
a major announcement has been made regarding the pricing of
the world's first malaria vaccine RTSs. The vaccine developed by GSK,
(00:20):
the nonprofit organization PATH and other partners, is set to
see its price slashed by more than half. According to
a commitment by drug makers Barrot Biotech and GSK, the
cost per dose will drop to less than five dollars
in endemic countries by twenty twenty eight. This reduction is
made possible through process improvements, expanded production capacity, and cost
(00:42):
effective manufacturing, along with minimal profit margins. The technology transfer
of production from GSK to Barrot Biotech, which began in
twenty twenty one, will be fully realized by twenty twenty eight,
facilitating this price cut. This price reduction is particularly significant
given the historical challenges in developing and distributing malaria vaccines.
(01:05):
Malaria vaccines have been in development since the nineteen sixties,
with substantial progress made in the last decade. The World
Health Organization WHO recommended the widespread use of the rts
SA zero one malaria vaccine among children in Sub Saharan
Africa and other regions with moderate to high malaria transmission
in October twenty twenty one. More recently, the WHO approved
(01:29):
a second malaria vaccine, R twenty one Matrix M for
use in malaria endemic countries. In addition to the pricing news,
there has been an innovative advancement in vaccine delivery technology.
Researchers from Oxford have developed programmable microcapsules that can deliver
vaccines in stages, potentially eliminating the need for booster shots.
(01:51):
This single shot malaria vaccine delivery system could transform global
immunization efforts by simplifying the vaccination process and improving compliance,
especially in regions where access to healthcare is limited. These
developments come as countries are ramping up their malaria vaccination programs.
For instance, Uganda recently launched the largest malaria vaccine introduction
(02:15):
to date, targeting one point one million children under two
years with the R twenty one Matrix M vaccine. This
vaccine is administered in four doses at six, seven, eight,
and eighteen months. The ongoing efforts to enhance malaria vaccination
highlight the complex challenges associated with developing vaccines against this parasite.
(02:36):
Malaria parasites have a complex life cycle and produce thousands
of potential antigens, making it difficult to achieve lifelong protection
through vaccination. However, current malaria vaccines such as rts S
and R twenty one matrix M have shown promising results,
reducing uncomplicated malaria by around forty percent, severe malaria by
(02:56):
about thirty percent, and all cause mortality by thirty ten.
As these advancements continue to shape the landscape of malaria prevention,
they underscore the commitment of global health organizations, researchers, and
pharmaceutical companies to combating this persistent and deadly disease.
Popular Podcasts
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.